(AOF) – Néovacs announces the superiority of its therapeutic messenger RNA (mRNA) vaccine, compared to the protein vaccine, in a preclinical trial in non-human primates for the treatment of allergies. This biotech which is developing new therapies for inflammatory and autoimmune diseases adds that in view of the results obtained with the mRNA approach, it has decided to extend the duration of this study to measure the effectiveness of mRNA type vaccines at long term (6 months).
According to Neovacs, the administration of the two vaccines was carried out without adverse effects in non-human primates and the study showed in both cases the induction of a neutralizing response against circulating cytokines IL-4 and IL-13. . The 3-month data also demonstrated significantly greater effectiveness of mRNA vaccines compared to protein vaccines.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.